News
1st pilot rapid assessment of WP5 JA2 Strand B on “Duodenal-jejunal bypass sleeve for the treatment of obesity with or without Type II Diabetes Mellitus”
The purpose of the assessment is to examine the effectiveness and safety of the duodenal-jejunal bypass sleeve/EndoBarrier® in in adults aged 18 years or older
The final version of the JA1 WP5 pilot assessment report is now published
We are pleased to present the final version of the WP5 JA1 pilot assessment using the draft model for Rapid Relative Effectiveness Assessment of Pharmaceuticals
Methodological guideline for REA of pharmaceuticals: Direct and indirect comparison
To make the best use of available evidence on the efficacy of a treatment, it is common to combine results from several randomised controlled trials
Methodological guideline for REA of pharmaceuticals: Criteria for the choice of the most appropriate comparator(s)
This document provides a summary of current national policies and best practice recommendations for HTA assessors for selecting the most appropriate comparator for relative effectiveness
Methodological guideline for REA of pharmaceuticals: Health-related quality of life
This guideline provides a set of recommendations for the selection and assessment of Health-related quality of life (HRQoL) when completing a Relative Effectiveness Assessment (REA)
Methodological guideline for REA of pharmaceuticals: Safety
This guideline aims at providing a framework for the evaluation of relative safety performed by HTA assessors in the context of Relative Effectiveness Assessment (REA)
Methodological guideline for REA of pharmaceuticals: Surrogate endpoints
This guideline provides a set of recommendations for the selection and assessment of surrogate endpoints when completing a Relative Effectiveness Assessment (REA) of pharmaceuticals. Surrogate
Methodological guideline for REA of pharmaceuticals: Clinical endpoints
This guideline provides a set of recommendations for the selection and assessment of clinical endpoints when completing a Relative Effectiveness Assessment (REA) of pharmaceuticals. Clinical
A new application of the HTA Core Model – the HTA Core Model for Rapid Relative Effectiveness Assessment of pharmaceuticals
The HTA Core Model defines the content elements to be considered in a health technology assessment (HTA) and facilitates standardised reporting. The aim is to
Public consultation on HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharmaceuticals
This document presents the public consultation of WP5 HTA Core Model® for Rapid Relative Effectiveness Assessment of Pharmaceuticals. The draft HTA Core Model® for Rapid
